156 related articles for article (PubMed ID: 21074222)
1. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
Martínez Pascual C; Valdés Mas M; de la Peña Moral JM; Miras López M
Med Clin (Barc); 2011 Sep; 137(7):329-30. PubMed ID: 21074222
[No Abstract] [Full Text] [Related]
2. [Survival following liver transplant due to imatinib-induced acute liver failure: a case study].
García-Valdés M; Miras López M; Garrido Corro B; De La Rubia Nieto A
Farm Hosp; 2012; 36(1):50-1. PubMed ID: 21514865
[No Abstract] [Full Text] [Related]
3. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
[TBL] [Abstract][Full Text] [Related]
4. [Severe imatinib-induced hepatotoxicity].
García Hernández FJ; González León R; Castillo Palma MJ; Sánchez Román J
Med Clin (Barc); 2012 May; 138(14):638; author reply 638-9. PubMed ID: 22137996
[No Abstract] [Full Text] [Related]
5. [Imatinib mesylate-induced acute cytolytic hepatitis].
Rocca P; El Jastimi S; Troncy J; Scoazec JY; Boucher A; Vial T; Trépo C; Zoulim F
Gastroenterol Clin Biol; 2004 Oct; 28(10 Pt 1):918-9. PubMed ID: 15523233
[No Abstract] [Full Text] [Related]
6. Nilotinib post-liver transplantation for acute hepatic failure related to imatinib.
Perini GF; Santos FP; Funke V; Ruiz J; Neto BH; Hamerschlak N
Leuk Res; 2009 Dec; 33(12):e234-5. PubMed ID: 19632720
[TBL] [Abstract][Full Text] [Related]
7. Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib.
Spataro V
J Clin Oncol; 2011 Jan; 29(3):e50-2. PubMed ID: 20956624
[No Abstract] [Full Text] [Related]
8. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Zonder JA; Schiffer CA
Curr Hematol Malig Rep; 2006 Sep; 1(3):141-51. PubMed ID: 20425345
[TBL] [Abstract][Full Text] [Related]
9. Histological features of acute hepatitis after imatinib mesylate treatment.
James C; Trouette H; Marit G; Cony-Makhoul P; Mahon FX
Leukemia; 2003 May; 17(5):978-9. PubMed ID: 12750713
[No Abstract] [Full Text] [Related]
10. Management of the new patient with CML in chronic phase.
Marin D
Curr Hematol Malig Rep; 2013 Mar; 8(1):37-42. PubMed ID: 23381448
[TBL] [Abstract][Full Text] [Related]
11. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
[No Abstract] [Full Text] [Related]
12. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
[No Abstract] [Full Text] [Related]
13. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
[No Abstract] [Full Text] [Related]
14. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
15. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Novitzky-Basso I; Craddock C
Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
[No Abstract] [Full Text] [Related]
16. Imatinib for chronic myeloid leukaemia: a NICE mess.
Lim D; Muir J
Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
[No Abstract] [Full Text] [Related]
17. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
18. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Schiffer CA
N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
[No Abstract] [Full Text] [Related]
19. A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.
Suemori K; Fujiwara H; Watanabe S; Azuma T; Yasukawa M
Int J Hematol; 2010 Dec; 92(5):777-8. PubMed ID: 21110146
[No Abstract] [Full Text] [Related]
20. [Imatinib-induced toxic hepatitis: description of two cases and review of the literature].
Fuster F; Medina L; Vallansot R; Granell M; Bruguera M
Gastroenterol Hepatol; 2007 Nov; 30(9):525-30. PubMed ID: 17980129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
